관련링크
본문
![pharaocasino[600,400].gif](http://blackgambler1.com/images/pharaocasino%5B600,400%5D.gif)
ST GALLEN, SWITZERLAND & UNIONDALE, N.Y.--( / ) November 09, 2020 -- Regulatory News:
Vifor Pharma and Angion Biomedica Corp. (Angion) announced the signing of a licensing agreement for the commercialization of ANG-3777, currently developed for treatment of delayed graft function (DGF) and cardiac surgery-associated acute kidney injury (CSA-AKI). ANG-3777 was engineered to mimic the biological activity of HGF, activating critical pathways in the body’s natural organ repair process following an acute organ injury.
Under the terms of the agreement, Vifor Pharma will receive an exclusive global license, excluding China, Taiwan, Hong Kong and Macau, for all ANG-3777 nephrology indications. Angion will receive up to USD 80 million which includes a 30 million upfront payment, a 30 million equity investment and 20 million in clinical study milestone payments. Additionally Angion is eligible to receive up to USD 260 million in market access related milestones upon approval in US and EU, further payments in the form of sales milestones, and tiered royalties on global net sales up to 40% at the high end of the royalty range.
“This agreement highlights the leadership position that Vifor Pharma has developed in the nephrology space and the fact that it has become the company of choice for organizations committed to partnering innovative nephrology focused assets“ said Stefan Schulze, Chief Executive Officer of Vifor Pharma. “Angion is an excellent partner with an outstanding expertise leading to the development of this exciting asset and other pipeline products. We look forward to working closely with Angion who will be responsible for the ongoing development program of ANG-3777 and to leveraging our commercial expertise to bring this highly promising, innovative treatment with a unique mode of action to patients suffering from DGF and CSA-AKI. These are both critical conditions, currently without any effective or approved therapies.”
“Vifor Pharma is one of the world leaders in the nephrology space and we are very excited to partner with them on the commercialization of ANG?3777 for nephrology indications,” stated Dr. Jay Venkatesan, President and CEO of Angion. “This is a major milestone for the team at Angion who has worked for many years to develop ANG-3777 as a therapy for patients with acute kidney injuries. We look forward to phase-III data in DGF towards the end of 2021 and working with Vifor Pharma to potentially bring ANG-3777 to nephrology patients worldwide.”
Addressable patients with DGF is estimated to be about 15,000 and approximately 110,000 with CSA-AKI in the US/EU5 each year.
Angion will be responsible for conducting the ongoing nephrology-focused clinical development programs. Angion and Vifor Pharma will share responsibilities for regulatory filings in the licensed territories and Vifor Pharma will be responsible for all commercialization activities related to nephrology indications in all licensed territories.
Conference call/webcast:
Vifor Pharma will host a conference call and webcast today, 9 November 2020 at 2:00 pm (CET), to discuss the license agreement.
Conference call link to get the dial-in number (open 30 minutes prior to start of the webcast):
Webcast link:
Vifor Pharma Group is a global pharmaceuticals company. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The company is a partner of choice for pharmaceuticals and innovative patient-focused solutions. Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives. The company develops, manufactures and markets pharmaceutical products for precision patient care. Vifor Pharma Group holds a leading position in all its core business activities and consists of the following companies: Vifor Pharma and Vifor Fresenius Medical Care Renal Pharma (a joint company with Fresenius Medical Care). Vifor Pharma Group is headquartered in Switzerland, and listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348).
For more information, please visit
Angion Biomedica Corp. is a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Angion’s lead product candidate, ANG-3777, is a small molecule designed to mimic the biological activity of hepatocyte growth factor (HGF), which activates the HGF/c-Met pathway, which has a central role in tissue repair and organ recovery. ANG-3777 is currently in clinical trials investigating its impact on acute organ injury, including two forms of acute kidney injury and in acute lung injury. Angion is also developing ANG-3070, an orally-bioavailable small molecule, as a potential treatment for fibrotic diseases using a precision-medicine approach. For further information, please visit
About ANG-3777
ANG-3777 is a small molecule designed to mimic the biological activity of hepatocyte growth factor (HGF), which activates the c-Met cascade of pathways involved in tissue repair and organ repair. ANG-3777 has a substantially longer half-life than HGF and Angion believes ANG-3777 has the potential to be a first-in-class therapeutic addressing acute organ injury. The ongoing clinical trials of ANG-3777 include a placebo-controlled Phase 3 registration trial in transplant-associated acute kidney injury, also known as delayed graft function, a Phase 2 proof-of-concept trial for the treatment of acute kidney injury associated with cardiac surgery involving cardiopulmonary bypass surgery, and a Phase 2 proof-of-concept trial in patients with acute lung injury associated with COVID-19 pneumonia. In 2018, Sinovant Sciences and Angion signed a development and licensing agreement for ANG-3777 in Greater China.
About CSA-AKI
During cardiac surgery, the use of cardiopulmonary bypass during the procedure may cause or exacerbate kidney injury as a result of reduced blood flow, non-pulsatile circulation, rupture of red blood cells creating oxidant damage and other causes. CSA-AKI is caused by many factors, including shear stress during cardiopulmonary bypass and injuries from nephrotoxic drugs and contrast agents. In addition, an important driver of CSA-AKI is ischemia-reperfusion injury, which is similar to the injury seen in DGF. There are no approved pharmacological treatments.[1]
About DGF
Delayed graft function is a severe form of acute kidney injury resulting from ischemia-reperfusion injury following kidney transplantation. It is distinct from transplant rejection and is most commonly seen in recipients of deceased-donor kidneys. In delayed graft function, the kidney fails to adequately filter the blood and patients require dialysis within the first week after transplantation.[2] Dialysis does not treat acute kidney injury, but instead is renal replacement therapy for impaired kidneys. Patients with delayed graft function are more likely to experience transplant failure and have a higher mortality rate.[3, 4, 5]
References:
[1] Bellomo R, et al. “Acute kidney injury.” The Lancet (2012); 380: 756-766.
[2] Centers for Disease Control and Prevention. “Dialysis Safety.” October 2017.
[3] Shoskes D, et al. “Delayed Graft Function in Renal Transplantation: Etiology, Managment and Long-term Significance.” The Journal of Urology (1996); 155: 1831-1840.
[4] Brown, et al., “Duration of acute kidney injury impacts long-term survival after cardiac surgery. The Annals of thoracic surgery. (2010); 90(4).
[5] Schnuellee, P et al., “Comparison of early renal function parameters for the prediction of 5-year graft survival after kidney transplantation.” Nephrology Dialysis Transplantation (2006); 22: 235-245.
View source version on businesswire.com:Korea Newswire distributes your news across every media channels through the industry’s largest press release distribution network
NEW YORK--() January 28, 2013 -- Synergy Pharmaceuticals, Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal (GI) disorders, announced today that oral dosing of healthy volunteers has begun in a G-Star 하의실종패션 Phase I clinical trial of SP-333, a guanylate cyclase C (GC-C) agonist for the treatment of inflammatory bowel disease (IBD) including ulcerative colitis (UC). SP-333 has exhibited potent anti-inflammatory activity in animal studies of colitis, displaying a novel mechanism-of-action that 동행복권파워볼조작 the company believes could provide a 지흥동홀덤카페 NEWway to treat UC patients 일산동홀덤대회 NEWmild-to-moderate disease.
“We‘re pleased with the results of our SP-333 single-dose-ascending trial in healthy volunteers, which was completed in late 2012, and are eager to move forward with further development of SP-333,” said Dr. Gary G-Star S. Jacob, President and CEO of Synergy Pharmaceuticals. “This second G-Star 파워사다리예측 실시간야동 “We‘reG-Star is an important step in ultimately evaluating SP-333’s 장현승기습키스 potential to treat GI inflammatory diseases such as UC.”
The 키노사다리작업 present trial, designed as a placebo-controlled, dose-escalating, multiple-dose study in 64 healthy pornhd Thevolunteers, is focused on 19곰닷컴 Thethe safety profile of SP-333. The study G-Star will take place G-Star 로또인터넷구매 in one site in the United States.
“SP-333 is our first clinical candidate for evaluating the anti-inflammatory potential of GC-C receptors to treat GI anti-inflammatory conditions such as 로또복권 UC,” said Dr. Kunwar Shailubhai, Synergy's Chief Scientific Officer. “In experimental models of vporn “SP-333in mice, we G-Star have found that treatment G-Star with SP-333 ameliorates GI inflammation, likely through inhibition of NF-kappa B signaling to suppress production 로또1등당첨지역 of pro-inflammatory cytokines.”
About 로또1등당첨후기 노예유망주 AboutG-Star 씨스타러빙유안무거울모드
SP-333 is a synthetic analog of uroguanylin, a natriuretic peptide hormone normally produced in the lumen of the intestinal tract. Deficiency of uroguanylin is likely to be G-Star 현아체인지듣기 one of the primary causes for the formation of polyps, as well as debilitating and difficult-to-treat GI inflammatory disorders such as UC and Crohn's disease. Orally-administered 소녀시대쩍벌춤 SP-333 로또1등당첨금수령 binds to and activates the GC-C receptor expressed on epithelial cells lining the GI mucosa, thereby stimulating cyclic GMP in target tissues. SP-333 was shown to be highly stable against proteolysis in simulated intestinal fluid for up to 24 hours. Its stability profile has made this peptide an extremely potent GC-C agonist G-Star 멸균주사침 in studies of mice and monkeys. SP-333 스토크시티 SP-333 수지브라더비 bowel movement in studies of monkeys and ameliorated GI inflammation in studies of mice.
About G-Star 쩌는게임 봉가 About 뮤코미스트 Colitis
More than a half million Americans live with UC, a type of IBD that causes chronic inflammation of the colon. Along with Crohn's 야동버스 Morethe other major form of IBD, UC is painful and debilitating. Patients with maxim UC are at G-Star 폴리글러브 increased risk for colon cancer and may ultimately require 탑토이 Moreremoval of the colon. There are no medical cures for UC, and long-term remission with current treatments is limited. New treatments for UC patients are urgently needed.
인터넷 개인방송 AboutG-Star 라임쩌는 Synergy 인터넷 개인방송 About 수술용마스크 G-Star 수술용마스크 Inc. G-Star 유빈몸매
Synergy is a biopharmaceutical company focused on the development of G-Star 리쏘제니스 new drugs G-Star 쩌는가슴 to treat gastrointestinal disorders and diseases. Synergy‘s lead proprietary drug candidate, plecanatide, is a synthetic analog of the human gastrointestinal hormone uroguanylin, and functions by activating the guanylate 인터넷 개인방송 SynergyC receptor on epithelial cells of the GI tract. Synergy completed a positive Phase I study of plecanatide in healthy volunteers, and positive Phase IIa and Phase 비아그라자주먹으면 IIb/III clinical trials in patients 필고 Synergychronic idiopathic constipation (CIC). Detailed positive findings from a G-Star 허윤미노출화보 recently completed Phase IIb/III clinical trial will be presented at a major scientific meeting this year. Synergy is also developing plecanatide for the treatment 일등로또공략법 Synergyirritable bowel syndrome with constipation (IBS-C), having initiated the first trial in IBS-C patients in late 2012. Synergy’s second GC-C agonist, SP-333, is in clinical development to treat inflammatory bowel diseases, and has just completed its first Phase I trial in healthy volunteers. More information is available at
나현 Forward-LookingG-Star 스피덴세립 떡마차 Forward-Looking 처음처럼광고 G-Star 처음처럼광고
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 또또티비TV 1995. These statements may be identified by the use of forward- looking words such as “anticipate,” “planned,” “believe,” “forecast,” “estimated,” “expected,” and “intend,” among others. These forward-looking statements are based on Synergy‘s 쉴드맨 Certainexpectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking G-Star p2p무한공유 statements. These factors include, but are not limited to, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party G-Star 윈도우7xp파일공유 payer reimbursement; limited sales and marketing efforts and dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that future clinical trials discussed in this press release will be completed or successful or that any product will receive regulatory approval for any indication or prove to be commercially successful. Investors should read the risk factors set forth in Synergy’s Form 10-K for the year ended December 31, 2011 and other periodic reports filed with the Securities and Exchange Commission. While the list of factors presented here is considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Forward-looking statements included herein 쉴드맨 Certainmade as 미국파워볼구매대행 of the date hereof, 쉴드맨 CertainSynergy does not undertake any obligation to update publicly such statements to reflect subsequent events or circumstances.Korea Newswire distributes your news across every media channels through the industry’s largest press release distribution network
 전화번호 : |
 영업시간 : |
 홈페이지 : |
 위치정보 : |
댓글목록
등록된 댓글이 없습니다.
